We're due for an announcement this week I reckon. Usually something comes out in the last week of each month.
Talking of big pharma interest, they're in the right business. These guys will have enough licensing agreements currently and in the pipe-line to stand on their own two feet, but they're also extremely susceptible to a takeover given the story with Domantis, Avidia and the general interest in the antibody field.
Their market cap is only 100 mill too, a large discount to what was paid for Domantis and Avidia
EGX
evogenix limited
